Long-acting growth hormone (LAGH) therapy is associated with a significant increase in Body Mass Index (BMI) Standard Deviation Scores (SDS) (+0.41) during the first 12 months of use.
Compared to daily recombinant human growth hormone (rhGH), LAGH treated patients showed a mean difference of 0.66 SDS in BMI at the 12-month mark.
Switching from daily rhGH to LAGH results in a pronounced BMI SDS increase (+0.75), while continuing LAGH maintains a steady BMI profile after the initial year.
Evidence suggests that lonapegsomatropin, somatrogon, and somapacitan share this metabolic trend, necessitating longitudinal anthropometric monitoring beyond height velocity.
